43. Future of Genetic Medicine w/ Scribe Therapeutics Founders - Ben Oakes & Dave Savage

 
 

Guests: Ben Oakes - Co-Founder & CEO @ Scribe Therapeutics

Dave Savage - Associate Professor @ UC Berkeley

Hosts: Chas Pulido (@AlixVentures) & Chris Ghadban

Ben Oakes is Co-founder, President, & CEO @ Scribe Therapeutics. He has contributed to over 25 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. A previous Innovative Genomics Institute Entrepreneurial Fellow, Ben has been named to the San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in biopharma, Business Insider 30 Under 40 transforming healthcare, and the Biocom Life Sciences Catalyst Awards. He received a PhD in Molecular and Cellular Biology from the University of California, Berkeley, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics.

&

Dave Savage is Co-founder & Scientific Advisor @ Scribe Therapeutics. He is an Associate Professor of Biochemistry, Biophysics, and Structural Biology at the University of California, Berkeley and in 2021 was selected as an Investigator of the Howard Hughes Medical Institute. Dave is an expert in biochemistry and protein engineering, and his laboratory develops novel tools for studying and manipulating the genome. Previously, he was a Department of Energy Physical Biosciences Fellow of the Life Sciences Research Foundation at Harvard Medical School.

Thank you for listening!

BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.

Music: Danger Storm by Kevin MacLeod (link & license

————————————————————————————————

Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.

Previous
Previous

44. Design Thinking in Biotech w/ Chris Garabedian - CEO @ Xontogeny / Former CEO @ Sarepta

Next
Next

42. Pharma BD to TechBio VC w/ Becky Pferdehirt - Partner @ Andreessen Horowitz (a16z Bio + Health Fund) & Seth Lieblich - Principal @ 8VC (Bio Team)